The patients were randomized into 2 cohorts assigned to receive either 1.0 mg ( 0.04 mL of 25 mg/mL ) subconjunctival bevacizumab ( treatment group ) or 0.04 mL of balanced salt solution ( control group ) injected in an identical manner posterior to the bleb after the bleb needling .